This is a free preview of a paid episode. To hear more, visit www.mendelspod.com

This week we welcome the innovative minds behind PredixBio, a new and groundbreaking company at the forefront of spatial biology. CEO Dusty Majumdar and co-founder Chakra Chennubhotla join us to discuss their mission to revolutionize cancer therapeutics through spatially intelligent biology. Founded in 2018 and supported by NIH grants, PredixBio focuses on unraveling the tumor microenvironment's heterogeneity using cutting-edge analytics and explainable AI. Their SpaceIQ platform integrates images and transcriptomics to predict patient responses to immunotherapy with an accuracy of over 90%.

Chakra studied under AI pioneer Geoffrey Hinton, often referred to as the "godfather" of AI. He explains the transformative potential of spatial analytics.

"Heterogeneity is not random; there is an order to it. Understanding this order allows us to uncover mechanisms hidden in the data."

Dusty highlights the company's mission, emphasizing the importance of explainability in AI for clinical trials and drug discovery.

"We don’t just provide predictions; we explain why patients respond—or don’t—to therapies. This helps redefine new targets and improves outcomes."

Join in to find out how PredxBio's new approach is setting new standards and shaping the future of spatial biology and precision medicine.